Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers.
Target Price
The average target price of ALZ.ST is 1.86 and suggests 105% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc